abstract |
The application describes a novel mechanism of action, that is modulation of the specific effectiveness of I-kappa-kinases or cyclic nucleotide phosphodiesterases (PDEs) which have the ability to cleave cGMP or cAMP. The preferred mode of action is dislocation, disruption of targeting or interference with redistribution of specific isoforms or splice variants of PDE4, PDE5, or I-kappa-kinases from their anchoring sites within cells, thereby modulating their specific effectiveness, not their enzymatic capacity. The chemical entities may be useful in preventing or treating in an animal, preferably a human, in need thereof an adverse condition which may be reduced or abolished by modulating the specific effectiveness of PDE4, PDE5, or I-kappa-kinases. |